Wamberg Genomic Advisors names new managing director.
M2 PHARMA-October 5, 2018-Wamberg Genomic Advisors names new managing director
(C)2018 M2 COMMUNICATIONS
Wamberg Genomic Advisors, a company involved in genomic testing, has named David Stertzer as its new managing director, it was reported yesterday.
Stertzer is the immediate past CEO and current advisor of AALU, an organisation involved in life insurance and annuities distribution in Washington, DC As the top officer at AALU for nearly thirty-three years, Stertzer is claimed to have provided continuity, leadership and strategic vision to AALU's board of directors.
In the new role, Stertzer will advise life insurance companies on genomic and advanced DNA program strategies.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 5, 2018|
|Previous Article:||ANI Pharmaceuticals launches Candesartan Hydrochlorothiazide Tablets.|
|Next Article:||Boston Pharmaceuticals signs licensing and equity agreement with Novartis.|